Mach7 Technologies Ltd. · ASX:M7T
Mach7 Technologies — H1 FY2023 Earnings Presentation
27 slides from Mach7 Technologies's earnings presentation, Feb 28, 2023
Slide 1: H1 FY23 Results Presentation
H1 FY23 Results Presentation February 28, 2023 Mach7 Technologies ASX: M7T 1
Slide 2: Disclaimer “forward looking” statements
Disclaimer “forward looking” statements Summary of information: This presentation contains general and background information about Mach7 Risks: An investment in M7T securities is subject to investment and other known and unknown risks, Technologies Limited (“M7T”) activities current as at the date
Slide 3: Agenda
Agenda Business Overview H1 FY23 Results Outlook • Our Business • Half-Year Highlights • Our Products • Record Sales Orders • Our Product Performance – Recurring fees feature Appendices • Our Customers – New customers & partners • Our Partners – Major contract wins • Record Revenue • Strong Financia
Slide 4: Business Overview
Business Overview Issued 18 February 2021, approved by the Board 4 4
Slide 5: Our Business
Our Business Mach7 – The Enterprise Imaging Solution Mach7’s medical imaging software solution centralises, stores, organises and displays patient data across the healthcare enterprise – connecting hospital networks and facilitating data flow between hospital departments and clinicians everywhere. T
Slide 6: Our Products
Our Products Enterprise Imaging – a focus on the entire healthcare network Mach7 provides an enterprise-wide interoperable platform for storing, retrieving and viewing all medical imaging data in one vendor neutral ecosystem. It comprises: Enterprise Data Management Enterprise Diagnostic Viewing Dep
Slide 7: Our Product Performance
Our Product Performance Best in KLAS 2023: Mach7 VNA Universal Viewer Segment Vendor Neutral Archive Placed #5 overall, outperforming #2 Placed #2 overall similar size and type vendor for second year in a row competitor (Hyland- Acuo). Held the #1 spot for Ranked alongside large legacy #1 PACS vendo
Slide 8: Our Customers
Our Customers World Market for Radiology IT – Select Product Markets (US$M) Integrated Delivery Independent 3,500 Networks (IDN) Provider Groups 3,000 International Medical Research 2,500 hospital authorities facilities and health systems 2,000 Regional and 1,500 Telehealth service community hospita
Slide 9: Our Partners
Our Partners Partnerships Partnerships represent 10% of Mach7’s H1 FY23 sales orders focused on meaningful value to support patient care Augmenting and expanding Mach7’s Enterprise Imaging Solution through innovative partnerships designed to enhance value to healthcare providers. 28 partnership solu
Slide 10: H1 FY23 Results
H1 FY23 Results Issued 18 February 2021, approved by the Board 10 10
Slide 11: Half Year Highlights
Half Year Highlights Record Sales Order Contracted Annual Annual Recurring growth (TCV)1 Record Revenue Recurring Revenue (ARR) $25.8M $16.4M3 Revenue (CARR) $16.4M run rate +$3.7M or 17% on PCP2 +$2.1M or 14% on PCP $20.0M +$3.0M or 22% on PCP +$3.2M or 19% on PCP Net Operating New contracts in EBI
Slide 12: Record Half Year Sales Orders – Recurring Fees Feature
Record Half Year Sales Orders – Recurring Fees Feature Recurring revenue a feature of sales orders Sales Orders By Fee Type Half Yearly Sales Orders Highlights: 30 30.0 (TCV in Constant Currency) 25 • Record sales orders of $25.8M (TCV), up 17% on $22.1M 35% in H1 FY22 (+5.4% on $24.6M in constant c
Slide 13: Record Half Year Sales Orders – New Customers and Partners
Record Half Year Sales Orders – New Customers and Partners New customers strengthen base for further growth H1 FY23 Sales Orders By Order Type (TCV) Renewal Highlights: $1.6 M 6% • New customer sales orders of $21.6M (83% of total sales Expansion orders) represented 3 new logos: Akumin, Nuvodia and
Slide 14: Record Half Year Sales Orders – Major Contract Wins
Record Half Year Sales Orders – Major Contract Wins New customers boost outpatient market exposure and expand Asian footprint Highlights: • St. Paul’s Hospital HK - a private hospital with ~500 beds and more than 20 departments. The capital contract has a year-one value of $1 million and TCV of $1.5
Slide 15: Record Revenue with Significant Recurring Component
Record Revenue with Significant Recurring Component Recurring revenue growth Recurring Revenue: CARR v ARR Highlights: 24 • Record Revenue of $16.4M; up 14% on $14.3M in H1 FY22, but lower than the $18.1M previously disclosed due to the $1.7M financing component of the 10-year Akumin 20 $3.6M contra
Slide 16: Strong Financials
Strong Financials EBITDA positive, healthy cash balance, no debt Highlights: Earnings H1 FY23 H1 FY22 % Change • Revenue growth trailing sales order growth as Revenues 16.4M 14.3 M +14% recognition of subscription/support and maintenance components of new orders require FPU which can take Distributo
Slide 17: Outlook
Outlook Efficiencies and Industry Brand awareness Sales opportunities economies sought transformation growing underpin targets Healthcare organisations are Remote reading services have Mach7 products continue to Sales pipeline replenished disaggregating single- become a business as usual rank highly
Slide 18: Appendices
Appendices Issued 18 February 2021, approved by the Board 18 18
Slide 19: KLAS – Defined
KLAS – Defined The Best in KLAS report recognises software and services companies who excel in helping healthcare professionals improve patient care. KLAS surveys healthcare IT customers (providers) throughout Best in KLAS is highly competitive and the calendar year and releases its final findings i
Slide 20: Our Value Proposition
Our Value Proposition Fits Individual Needs Designed for the Enterprise Flexible Workflows We can fit into customers’ existing The foundation is in the enterprise, not Flexibility of workflows – with an intuitive technology infrastructure or adapt as it individual departmental systems. The Mach7 and
Slide 21: Our Differentiators
Our Differentiators • Enterprise First Strategy • Top Product Rankings • VNA backend data management solution • Mach7’s Viewer ranked #2 and VNA ranked #5 designed and built for entire healthcare by independent customer survey. Features network rather than the radiology department include intuitive
Slide 22: Our Global Footprint
Our Global Footprint >150 Customers 15 Countries Australia Canada China France Hong Kong Indonesia Italy Netherlands Qatar Philippines Singapore Saudi Arabia Hospital United Kingdom systems around United States the world use Mach7 Vietnam Technologies = Primary Markets = Global Presence 22
Slide 23: Our Revenue Model
Our Revenue Model Revenue model caters to client funding needs Flexible revenue model allows for both subscription (“SaaS”) and capital licences, generally on 5-year terms. Equivalent Contracts: Capital Licence Subscription Licence Activity/Timing Fee Type Revenue Contribution Revenue Contribution R
Slide 24: Our Leadership Team
Our Leadership Team Mike Lampron Dyan O’Herne David Madaffri Ravi Krishnan Chief Executive Interim Global General Officer Chief Financial Vice President, Manager, Officer Sales APAC Mike is the CEO of Mach7 Technologies. With over 20 years of Dyan has been with Mach7 for seven years in financial Dav
Slide 25: Our Board of Directors
Our Board of Directors David Chambers Mike Lampron Philippe Houssiau Non-Executive Chairman Managing Director Non-Executive Director David has more than 30 years’ extensive experience in the Healthcare and Life Science Mike is the Chief Executive Officer and Managing Director of Mach7 Technologies.
Slide 26: Our ASX Listing
Our ASX Listing Corporate Snapshot 12-month share price performance ASX Code M7T Share Price (24 February 2023) $0.69 $0.80 Market Capitalisation (24 February 2023) $165M $0.75 Shares on Issue 239.7M $0.70 Number of Shareholders 5,891 $0.65 We have grown from a culture Substantial Shareholders of in
Slide 27: Contact Us
Contact Us Investor Relations, Mach7: Rebecca Thompson +61 (0) 416 079 329 Rebecca.Thompson@mach7t.com Registered Office: Level 4 | 100 Albert Road, South Melbourne, VIC This document was authorised for release to the ASX by Mike Lampron, Managing Director and Chief Executive Officer Issued 18 Febru